Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer

Radiotherapy and Oncology

Volumn 103, Issue 1, 2012, Pages 88-91

  Bhide, Shreerang A ^a,b   Gulliford, Sarah ^b   Schick, Ulrike ^a   Miah, Aisha ^a   Zaidi, Shane ^a   Newbold, Katie ^a   Nutting, Christopher M ^a,b   Harrington, Kevin J ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Acute dysphagia; Acute mucositis; Chemo IMRT; Dose response curves; Head and neck cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; CURVE FITTING; DISEASE SEVERITY; DOSIMETRY; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MODEL; MOUTH INFLAMMATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME;

ACUTE DISEASE; CHEMORADIOTHERAPY; DEGLUTITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; STOMATITIS;

EID: 84859728689     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.12.027     Document Type: Article

References (41)

1. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55. (Pubitemid 30148259)
2. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
3. Lefebvre JL. Laryngeal preservation in head and neck cancer: multidisciplinary approach. Lancet Oncol 2006;7:747-55. (Pubitemid 44283668)
4. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-9. (Pubitemid 26230640)
5. Monnerat C, Faivre S, Temam S, et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13:995-1006.
6. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000;83:1594-8. (Pubitemid 32001699)
7. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004;96:1714-7. (Pubitemid 39591589)
8. Bhide SA, Ahmed M, Barbachano Y, et al. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer 2008;99:57-62.
9. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253-62. (Pubitemid 36556043)
10. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838-47. (Pubitemid 26085529)
11. Jackson SM, Weir LM, Hay JH, et al. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;43:39-46. (Pubitemid 27191977)
12. Maciejewski B, Skladowski K, Pilecki B, et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiother Oncol 1996;40:137-45. (Pubitemid 26276678)
13. Bourhis J, Lapeyre M, Tortochaux J, et al. Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. Radiother Oncol 2011;100:56-61.
14. Bentzen SM. Radiobiological considerations in the design of clinical trials. Radiother Oncol 1994;32:1-11. (Pubitemid 24246758)
15. Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol 2003;13:189-202. (Pubitemid 36962643)
16. Miah AB, Bhide SA, Guerrero-Urbano MT, et al. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2012;82:539-47.
17. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704. (Pubitemid 32515326)
18. Guerrero Urbano T, Clark CH, Hansen VN, et al. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol 2007;85:36-41. (Pubitemid 47570062)
19. Withers HR, Thames Jr HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol 1983;1:187-91. (Pubitemid 14182317)
20. DTCD N, NIH, DHHS. Common terminology criteria for adverse events, version 3.0.
21. Bentzen SM. Dose-response relationships in radiotherapy. In: Steel GG, editor. Basic clinical radiobiology. London: Arnold; 2002. p. 94-104.
22. Jackson A, Ten Haken RK, Robertson JM, et al. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys 1995;31:883-91.
23. Sanguineti G, Gunn GB, Parker BC, et al. Weekly dose-volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2011;79:52-9.
24. Rancati T, Schwarz M, Allen AM, et al. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys 2010;76:S64-9.
25. Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 2010;76:S155-60.
26. Bhide SA, Gulliford S, Fowler J, et al. Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. Radiother Oncol 2010;97:86-91.
27. Denham JW, Walker QJ, Lamb DS, et al. Mucosal regeneration during radiotherapy. Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol 1996;41:109-18.
28. Dorr W, Hamilton CS, Boyd T, et al. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002;52:911-7. (Pubitemid 34219008)
29. Bentzen SM, Saunders MI, Dische S, et al. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001;60:123-35. (Pubitemid 32601965)
30. Fowler JF. Apparent rates of proliferation of acutely responding normal tissues during radiotherapy of head and neck cancer. Int J Radiat Oncol Biol Phys 1991;21:1451-6.
31. Kaanders JH, van Daal WA, Hoogenraad WJ, et al. Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity. Int J Radiat Oncol Biol Phys 1992;24:497-503.
32. Thames HD, Bentzen SM, Turesson I, et al. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol 1990;19:219-35. (Pubitemid 20369216)
33. Scott-Brown M, Miah A, Harrington K, et al. Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. Radiother Oncol 2010;97:249-57.
34. Koiwai K, Shikama N, Sasaki S, et al. Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers. Radiother Oncol 2010;97:132-5.
35. van der Laan HP, Christianen ME, Bijl HP, et al. The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: An in silico planning comparative study. Radiother Oncol 2012;103:76-81.
36. Simone 2nd CB, Ly D, Dan TD, et al. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. Radiother Oncol 2011;101:376-82.
37. Cheng SS, Terrell JE, Bradford CR, et al. Variables associated with feeding tube placement in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:655-61. (Pubitemid 43927044)
38. Langendijk JA, Doornaert P, Rietveld DH, et al. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 2009;90:189-95.
39. Mangar S, Slevin N, Mais K, et al. Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: a retrospective review. Radiother Oncol 2006;78:152-8. (Pubitemid 43344174)
40. Chen AM, Li BQ, Lau DH, et al. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2010;78:1026-32.
41. Clavel S, Fortin B, Despres P, et al. Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach. Int J Radiat Oncol Biol Phys 2011;79:763-9.